메뉴 건너뛰기




Volumn 16, Issue 1, 2014, Pages 165-

Challenging cytomegalovirus data in glioblastoma

Author keywords

[No Author keywords available]

Indexed keywords

EARLY ANTIGEN; VALGANCICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR;

EID: 84891553747     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not212     Document Type: Letter
Times cited : (10)

References (5)
  • 1
    • 84879247198 scopus 로고    scopus 로고
    • Effects of valganciclovir as an add-on therapy in patientswith cytomegalovirus-positive glioblastoma: A randomized, double-blind, hypothesis-generating study
    • Stragliotto G, Rahbar A, Solberg NW, et al. Effects of valganciclovir as an add-on therapy in patientswith cytomegalovirus-positive glioblastoma: A randomized, double-blind, hypothesis-generating study. Int J Cancer. 2013;133:1204-1213
    • (2013) Int J Cancer , vol.133 , pp. 1204-1213
    • Stragliotto, G.1    Rahbar, A.2    Solberg, N.W.3
  • 2
    • 84883439743 scopus 로고    scopus 로고
    • Survival in patients with glioblastoma receiving valganciclovir
    • Söderberg-Nauclé r C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med. 2013;369: 985-986
    • (2013) N Engl J Med , vol.369 , pp. 985-986
    • Söderberg-Nauclér, C.1    Rahbar, A.2    Stragliotto, G.3
  • 3
    • 20044366163 scopus 로고    scopus 로고
    • Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
    • Stupp R, Mason W, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996
    • (2005) N Engl J Med , vol.352 , pp. 987-996
    • Stupp, R.1    Mason, W.2    Van Den Bent, M.J.3
  • 4
    • 84891532999 scopus 로고    scopus 로고
    • Phase iii trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: Mature progression-free survival and preliminary overall survival results in avaglio
    • Abstract OT-03. November 15-18 2012. Washington, D.C. Neuro Oncol 2012 Oct 14(Suppl 6): Vi101
    • Chinot O, Wick W, Mason W, et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: Mature progression-free survival and preliminary overall survival results in AVAglio. 17th Annual Meeting of the Society for Neuro-Oncology. Plenary Session 5. Abstract OT-03. November 15-18, 2012. Washington, D.C. Neuro Oncol 2012 Oct; 14(Suppl 6): Vi101
    • 17th Annual Meeting of the Society for Neuro-Oncology Plenary Session , vol.5
    • Chinot, O.1    Wick, W.2    Mason, W.3
  • 5
    • 84880791777 scopus 로고    scopus 로고
    • Molecular neuro-oncology in clinical practice: A new horizon
    • Weller M, Pfister SM, Wick W, et al. Molecular neuro-oncology in clinical practice: A new horizon. Lancet Oncol. 2013;14: E370-e379
    • (2013) Lancet Oncol , vol.14
    • Weller, M.1    Pfister, S.M.2    Wick, W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.